Related Experiment Videos
Latanoprost for uncontrolled glaucoma in a compassionate case protocol
B Patelska1, D S Greenfield, J M Liebmann
1Department of Ophthalmology, New York Eye and Ear Infirmary, New York 10003, USA.
American Journal of Ophthalmology
|January 24, 1998
Summary
Latanoprost eye drops significantly lowered intraocular pressure in glaucoma patients already on maximum treatment. This adjunctive therapy offers further reduction, with 44% achieving a 20% decrease in pressure.
Area of Science:
- Ophthalmology
- Pharmacology
Background:
- Glaucoma management often requires maximal tolerated medical therapy to control intraocular pressure (IOP).
- Further IOP reduction is crucial for preventing optic nerve damage and vision loss in advanced glaucoma.
Purpose of the Study:
- To assess the efficacy of latanoprost 0.005% as an add-on treatment for patients with glaucoma.
- To evaluate the ocular hypotensive effect of latanoprost in patients already on maximal medical therapy.
Main Methods:
- A compassionate clinical trial enrolled 160 patients with glaucoma receiving maximal medical therapy.
- Latanoprost 0.005% was administered nightly, with IOP measured at 1, 3, and 6 months.
- Responders were defined as achieving at least a 20% reduction in IOP from baseline.
Main Results:
- Mean baseline IOP was 23.3 +/- 6.9 mm Hg, with significant reductions observed at all follow-up intervals (P < .01).
- 44.4% of patients achieved at least a 20% IOP reduction at 1 month, with similar rates at 3 and 6 months.
- Ocular allergy or irritation occurred in 5.0% of patients, leading to treatment cessation.
Conclusions:
- Latanoprost 0.005% demonstrates significant ocular hypotensive efficacy as adjunctive therapy in glaucoma patients.
- This treatment offers a valuable option for further IOP control when maximal therapy is insufficient.